Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Solid Tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,545 result(s) found for: Solid Tumor. Displaying page 12 of 78.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    EudraCT Number: 2020-004770-22 Sponsor Protocol Number: TAS-117-201 Start Date*: 2021-04-01
    Sponsor Name:Taiho Oncology, Inc.
    Full Title: A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations
    Medical condition: Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations
    Disease: Version SOC Term Classification Code Term Level
    23.0 10010331 - Congenital, familial and genetic disorders 10071986 PTEN gene mutation PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001277-24 Sponsor Protocol Number: 20130111 Start Date*: 2014-01-20
    Sponsor Name:Amgen Inc
    Full Title: A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Ade...
    Medical condition: MET Amplified Gastric (G), Gastroesophageal Junction (GEJ), or Esophageal (E) Adenocarcinoma or Other MET Amplified Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) DE (Completed) BE (Completed) GB (Completed) IT (Completed) AT (Completed) HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002766-14 Sponsor Protocol Number: 2020-3093 Start Date*: 2020-10-26
    Sponsor Name:Gustave Roussy
    Full Title: An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors
    Medical condition: Patients with DNA repair-deficient or platinum-sensitive solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003947-27 Sponsor Protocol Number: TAK-981-1002 Start Date*: 2021-07-04
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumor...
    Medical condition: Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
    Disease: Version SOC Term Classification Code Term Level
    27.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023156-89 Sponsor Protocol Number: V212-011 Start Date*: 2011-02-24
    Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc
    Full Title: Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica. A Phase III Rando...
    Medical condition: Incidence of Herpes Zoster in adults with solid tumor or hematologic malignancy Incidencia de Herpes Zoster en pacientes adultos con tumor sólido o neoplasia hematológica.
    Disease: Version SOC Term Classification Code Term Level
    13 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) CZ (Completed) GB (Completed) SK (Completed) AT (Completed) BE (Completed) EE (Completed) LT (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002423-29 Sponsor Protocol Number: INCB24360-204 Start Date*: 2017-07-13
    Sponsor Name:incyte Corporation
    Full Title: A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers
    Medical condition: Selected advanced cancers, including metastatic and/or unresectable solid tumors including NSCLC, melanoma,adenocarcinoma of the colon or rectum , recurrent squamous cell carcinoma of the head and ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000036-57 Sponsor Protocol Number: D9570C00001 Start Date*: 2022-05-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in...
    Medical condition: Advanced or Metastatic Non-small Cell Lung Carcinoma Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005028-13 Sponsor Protocol Number: MK-6482-015 Start Date*: 2021-07-19
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendoc...
    Medical condition: Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumor or von Hippel-Lindau (VHL) Disease-Associated Tumors or Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors with HIF...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10034876 Pheochromocytoma LLT
    20.0 100000004864 10073860 Paraganglioma LLT
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10047716 Von Hippel-Lindau disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001119-30 Sponsor Protocol Number: 2B3-101-CR-001 Start Date*: 2011-06-22
    Sponsor Name:to-BBB technologies B.V.
    Full Title: An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma.
    Medical condition: Solid tumors and brain metastases or recurrent malignant glioma, HER2-positive adenocarcinoma of the breast with brain metastases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001847-16 Sponsor Protocol Number: BO41932 Start Date*: 2021-03-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL
    Medical condition: Locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by a validated NGS assay
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000547-14 Sponsor Protocol Number: BGOG-cx3 Start Date*: 2017-08-30
    Sponsor Name:BGOG-UZLeuven
    Full Title: BGOG-cx3: Prospective randomized Phase II trial comparing doxorubicin alone versus doxorubicin and atezolizumab in recurrent cervical cancer
    Medical condition: recurrent cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005575-12 Sponsor Protocol Number: BYON5667.002 Start Date*: 2021-06-30
    Sponsor Name:Byondis B.V.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in period to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular tox...
    Medical condition: Single arm run-in period: Patients with solid tumours (excluding gastric tumours and adenocarcinomas of the gastroesophageal junction) Randomized part of the study: patients with locally advanced ...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-004122-22 Sponsor Protocol Number: APHP220097 Start Date*: 2023-06-02
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
    Full Title: Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer
    Medical condition: adult patients in all MSI/DMMR solid tumor types
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012964-14 Sponsor Protocol Number: XL184-203 Start Date*: 2010-03-10
    Sponsor Name:Exelixis Inc
    Full Title: A randomized discontinuation study of XL184 in subjects with advanced solid tumors
    Medical condition: To evaluate the efficacy of XL184 in subjects with one of the following advanced solid tumors: a. Breast Cancer b. Gastric and Gastroesophageal Junction Cancer c. Hepatocellular Carcinoma (HCC) ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010551-26 Sponsor Protocol Number: D0102C00003 Start Date*: 2009-08-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a S...
    Medical condition: Phase I part of the study: Solid tumours that are refractory to standard therapies Phase II part of the study: trastuzumab- or lapatinib-ineligible patients with locally advanced (not amenable to s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049280 Solid tumour LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) HU (Completed) SE (Completed) FR (Completed) IT (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003614-24 Sponsor Protocol Number: CLTT462X2101 Start Date*: 2016-03-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I dose finding study of oral LTT462 in adult patients with advanced solid tumors harboring MAPK pathway alterations
    Medical condition: Adult and adolescent patients with advanced solid tumors harboring MAPK pathway alterations
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002354-12 Sponsor Protocol Number: CMBG453X2101 Start Date*: 2016-02-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005019-34 Sponsor Protocol Number: CTMT212X2106 Start Date*: 2016-05-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors
    Medical condition: Solid tumors, Pancreatic Cancer, Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002368-30 Sponsor Protocol Number: D967MC00001 Start Date*: 2021-04-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activ...
    Medical condition: Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Trial now transitioned) FR (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000441-41 Sponsor Protocol Number: NB-ND021(NM21-1480)-101 Start Date*: 2021-10-26
    Sponsor Name:Numab Therapeutics AG
    Full Title: A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 10:35:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA